Scarica l'app Stockscreener
12.84
6.14%
-0.84
Dopo l'orario di chiusura:
12.77
-0.07
-0.55%
Precedente Chiudi:
$13.68
Aprire:
$13.76
Volume 24 ore:
1.74M
Relative Volume:
1.06
Capitalizzazione di mercato:
$938.21M
Reddito:
-
Utile/perdita netta:
$-148.00M
Rapporto P/E:
-2.8985
EPS:
-4.4299
Flusso di cassa netto:
$-135.66M
1 W Prestazione:
+9.09%
1M Prestazione:
+28.27%
6M Prestazione:
+123.69%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.78
$13.92
Intervallo di 1 settimana:
$11.44
$13.92
Portata 52W:
$3.76
$14.35
Helus Pharma Inc Stock (HELP) Company Profile
Nome
Helus Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare HELP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
12.84 | 999.59M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | TD Cowen | Buy |
| 2026-02-02 | Iniziato | Jefferies | Buy |
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Borsa (HELP) Ultime notizie
HELP News Today | Why did Cybin stock drop today? $HELP - marketbeat.com
Phase 3 depression drug in focus as Cybin's Helus Pharma (HELP) joins Morgan Stanley event - Stock Titan
Cybin (NASDAQ:HELP) Shares Down 5.5%Here's Why - marketbeat.com
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkThu, 09/10/202607:30 - Helus Pharma
Executive chair buys 95,000 Cybin (HELP) shares in latest stake filing - Stock Titan
Helus Pharma (Nasdaq: HELP) CEO joins NYC investor fireside chat on Sept. 14 - Stock Titan
Cybin (HELP) growth chief buys 90,000 shares in $1.04M trade - Stock Titan
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New YorkWed, 09/09/202607:30 - Helus Pharma
symbol__ Stock Quote Price and Forecast - CNN
HELP Watch: What's Behind Cybin Inc.'s Latest Move - kalkine.ca
Co-Founder of Cybin Picks Up 2.2% More Stock - simplywall.st
HELP Should I Buy - Intellectia AI
CYBIN (NASDAQ: HELP) to Host Webcast and Replay for September 11 Cantor Global Healthcare Conference - Kalkine Media
Canaccord Genuity maintains Buy on Helus Pharma, cuts target to $42 - scanx.trade
Investors can stream Helus Pharma (NASDAQ: HELP) CEO at Cantor event - Stock Titan
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York - Investing News Network
New Cybin (HELP) stock options run to 2036 with $261,987 in potential proceeds - Stock Titan
Cybin (HELP) Is Up 19.8% After Deepening Psychedelic Pipeline And Leadership Shift Is The Risk Story Changing? - simplywall.st
Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions - Yahoo Finance
Helus Pharma advances psychedelic treatments fo... - Pluang
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst - Seeking Alpha
Cybin Stock Advances 5.23% as Phase 3 Depression Program, Leadership Expansion and Late-Stage Catalysts Lift Optimism - kalkine.ca
HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62 - Yahoo Finance
HELP Maintained by TD Cowen -- Price Target Raised to $62 - GuruFocus
TD Cowen raises Helus Pharma stock price target to $62 on trial timing - Investing.com
Cybin (NYSE: HELP) plans 1.18M RSUs with first sale in 2026 - Stock Titan
Cybin Inc. (HELP) sets performance share plan through 2029 - Stock Titan
Helus Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Cybin (HELP) execs granted $12.6M shares as holders face 82% loss - Stock Titan
Helus Pharma Strengthens Leadership with Key Appointments as Pipeline Advances - citybuzz -
Cybin (HELP) adds exhibit to its base shelf registration - Stock Titan
How Helus’ new CEO plans to scale its psychedelic drug pipeline - Pharma Voice
Helus Pharma appoints former Intra-Cellular executives By Investing.com - Investing.com Canada
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory BoardTue, 08/18/202607:30 - Helus Pharma
Helus Pharma reports fiscal 2026 results, advances HLP003 trial - scanx.trade
Helus Pharma Inc (HELP) Q1 2026 Results Highlight Unprofitable S - GuruFocus
Helus Pharma Q1 Results: Net loss widens to $47.8M, cash at $166.4M - scanx.trade
Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares - Stock Titan
Cybin : MDA Q1 27 FINAL - marketscreener.com
Cybin : Financial Statements Q1 27 FINAL - marketscreener.com
Helus Pharma (HELP) pushes Phase 3 depression and anxiety drug programs while managing cash needs - Stock Titan
Helus Pharma Appoints Michael Halstead CEO, Completes Enrollment in Phase 3 APPROACH Study of HLP003 and Reports Q2 2026 Results - Quiver Quantitative
Canada's Helus Pharma Q1 loss widens as R&D spending rises - TradingView
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business HighlightsFri, 08/14/202607:28 - ir.helus.com
Helus Pharma finishes Phase 3 depression trial enrollment - Stock Titan
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 - MarketBeat
Helus Pharma (CN: HELP) Names New CEO as Pivotal Depression Trial Nears Its Finish Line - kalkine.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Cybin Stock Builds Bullish Momentum as Clinical Catalysts Strengthen the HELP Outlook - kalkine.ca
Helus Pharma at Canaccord Genuity growth conference: phase iii test looms - Investing.com Nigeria
Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares - stocktitan.net
Helus Pharma Inc Azioni (HELP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):